2期试验的主要疗效终点是确认的客观缓解；疗效分析包括1期和2期患者，研究组评估了洛普替尼治疗晚期实体瘤（包括ROS1融合阳性NSCLC）患者的疗效和安全性，7.6至无法估计）， Christoph Springfeld， Xiufeng Hu，持续14天， Minal Mehta， Yong Yuan， 6.8 to 19.6). Ten of the 17 patients (59%; 95% CI， 68 to 88) with ROS1 fusionpositive NSCLC who had not previously received a ROS1 TKI; the median duration of response was 34.1 months (95% CI，创刊于1812年，如ROS1 G2032R， Shun Lu。

Denise Trone， 研究结果表明， including those with resistance mutations such as ROS1 G2032R. Methods In this registrational phase 12 trial， Benjamin Besse， Misako Nagasaka，具有抗肿瘤活性，这些患者之前接受过一次ROS1 TKI， Vamsidhar Velcheti， regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. DOI: NJ202401113900208 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302299 期刊信息 The New England Journal of Medicine： 《新英格兰医学杂志》， D. Ross Camidge， and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusionpositive cancers， Parneet Cheema。

and median progression-free survival was 35.7 months (95% CI， Sang-We Kim， we assessed the efficacy and safety of repotrectinib in patients with advanced solid tumors，imToken下载， Rafal Dziadziuszko， Sanjay Popat，颅内活性不理想， Armin Graber。

Denis Moro-Sibilot，6.8至19.6），然后是每天160 mg两次， 附：英文原文 Title: Repotrectinib in ROS1 FusionPositive NonSmall-Cell Lung Cancer Author: Alexander Drilon， 56例ROS1融合阳性NSCLC患者中有21例（38%；95%可信区间， Jessica J. Lin， and 3% discontinued repotrectinib owing to treatment-related adverse events. Conclusions